1. Human cytomegalovirus-platelet interaction triggers toll-like receptor 2-dependent proinflammatory and proangiogenic responses.
- Author
-
Assinger A, Kral JB, Yaiw KC, Schrottmaier WC, Kurzejamska E, Wang Y, Mohammad AA, Religa P, Rahbar A, Schabbauer G, Butler LM, and Söderberg-Naucler C
- Subjects
- Adenosine Diphosphate metabolism, Animals, Atherosclerosis immunology, Atherosclerosis metabolism, Atherosclerosis virology, Blood Platelets drug effects, Blood Platelets immunology, CD40 Ligand metabolism, Cell Degranulation, Cells, Cultured, Humans, Inflammation immunology, Inflammation metabolism, Inflammation virology, Interleukin-1beta metabolism, Mice, Mice, Inbred C57BL, Mice, Knockout, Neutrophil Activation, Neutrophils immunology, Neutrophils metabolism, Neutrophils virology, Platelet Activation drug effects, Purinergic P2Y Receptor Antagonists pharmacology, Receptors, Purinergic P2 drug effects, Receptors, Purinergic P2 metabolism, Signal Transduction drug effects, Time Factors, Toll-Like Receptor 2 deficiency, Toll-Like Receptor 2 genetics, Transendothelial and Transepithelial Migration, Vascular Endothelial Growth Factor A metabolism, Blood Platelets metabolism, Blood Platelets virology, Cytomegalovirus pathogenicity, Inflammation etiology, Inflammation Mediators metabolism, Neovascularization, Pathologic, Toll-Like Receptor 2 metabolism
- Abstract
Objective: Human cytomegalovirus (HCMV) is a widespread pathogen that correlates with various clinical complications, including atherosclerosis. HCMV is released into the circulation during primary infection and periodic viral reactivation, allowing virus-platelet interactions. Platelets are important in the onset and development of atherosclerosis, but the consequences of platelet-HCMV interactions are unclear., Approach and Results: We studied the effects of HCMV-platelet interactions in blood from healthy donors using the purified clinical HCMV isolate VR1814. We demonstrated that HCMV bound to a Toll-like receptor (TLR) 2-positive platelet subpopulation, which resulted in signal transduction, degranulation, and release of proinflammatory CD40L and interleukin-1β and proangiogenic vascular endothelial-derived growth factor. In mice, murine CMV activated wild-type but not TLR2-deficient platelets. However, supernatant from murine CMV-stimulated wild-type platelets also activated TLR2-deficient platelets, indicating that activated platelets generated soluble mediators that triggered further platelet activation, independent of TLR2 expression. Inhibitor studies, using ADP receptor antagonists and apyrase, revealed that ADP release is important to trigger secondary platelet activation in response to HCMV. HCMV-activated platelets rapidly bound to and activated neutrophils, supporting their adhesion and transmigration through endothelial monolayers. In an in vivo model, murine CMV induced systemic upregulation of platelet-leukocyte aggregates and plasma vascular endothelial-derived growth factor in mice and showed a tendency to enhance neutrophil extravasation in a TLR2-dependent fashion., Conclusions: HCMV is a well-adapted pathogen that does not induce immediate thrombotic events. However, HCMV-platelet interactions lead to proinflammatory and proangiogenic responses, which exacerbate tissue damage and contribute to atherogenesis. Therefore, platelets might contribute to the effects of HCMV in accelerating atherosclerosis.
- Published
- 2014
- Full Text
- View/download PDF